Le Lézard
Classified in: Health, Science and technology
Subjects: Stock Sale/Buyback, Share Issue

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares


Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 8,547,297 shares of common stock, including 1,114,864 shares sold upon full exercise of the underwriters' option to purchase additional shares, at a price to the public of $74.00 per share. The net proceeds to Veracyte from the offering were approximately $593.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Goldman Sachs & Co., LLC and SVB Leerink LLC acted as joint lead book-running managers for the offering. William Blair & Company, L.L.C. acted as a book-running manager and BTIG, LLC, Needham & Company, LLC, and Lake Street Capital Markets, LLC acted as co-managers.

The public offering was made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on February 3, 2021. This offering was made solely by means of a prospectus supplement and accompanying prospectus relating to and describing the terms of the offering, copies of which may be obtained by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by email at [email protected], or by telephone at (866) 471-2526; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 01220, by email at [email protected], or by telephone at (800) 808-7525, ext. 6105.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Veracyte, Afirma, Percepta, Envisia, Prosigna, "Know by Design" and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are Veracyte's registered trademarks in the U.S. and selected countries.


These press releases may also interest you

at 13:10
Bilateral Chamber, a leading organization at the forefront of global commerce, hosted His Excellency Mohammed Shyaa Sabbar Al-Sudani, Prime Minister of the Republic of Iraq and his delegation yesterday in Houston, Texas. The Iraqi Prime Minister was...

at 13:05
Versa Networks, the global leader in AI/ML-powered Unified Secure Access Service Edge (SASE) and Software Defined WAN (SD-WAN), today announced it is recognized in the Gartner Magic Quadrant for Security Service Edge (SSE) which will help buyers...

at 13:04
Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch ? Sirolimus drug coated balloon (DCB), for the management of in-stent...

at 12:59
Fusion Academy, the world's most personalized school with one-to-one classes to match students' pace and preference, is pleased to announce its 2024 Spring Virtual College Week, taking place from April 22 to April 25. This unique online program is...

at 12:55
Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of its client S&L Computer Services, Inc. to Cyber Advisors (a portfolio company of Goldner Hawn). The acquisition...

at 12:45
Beaverlab today announced the launch of a Kickstarter campaign for its new Excope DT1 camera. Excope DT1 is the world's lightest, portable super-telephoto camera for photos and videos. It is versatile, relieving photographers from the hassle of...



News published on and distributed by: